UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended July 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from [●] to [●] Commission File Number: 001-40101 | --- | --- | |-------------------------------------------------------------------------------------------------------------- ...

Exhibit 99.1 BriaCell Therapeutics Corp. Condensed Interim Consolidated Financial Statements For the Three and Nine Months Ended April 30, 2022 Expressed in United States Dollars (Unaudited) | --- | --- | |-------------------------------------|-------------------------------------| | | | | Corporate Office- Canada | | | Suite 300 - Bellevue Centre | Corporate Office- US | | 235 -15th Street | 2929 Arch Street, 3rd Floor | | West Vancouver, BC V7T 2X1 | Philadelphia, PA 19104 | | Tel : 604-921-1810 | Tel : 1 ...

Exhibit 99.3 BRIACELL THERAPEUTICS CORP. Annual Information Form FOR THE YEAR ENDED JULY 31, 2021 DATED AS OF OCTOBER 28, 2021 TABLE OF CONTENTS | --- | --- | |--------------------------------------------------------------------------|-------| | | | | ANNUAL INFORMATION FORM | 1 | | FORWARD-LOOKING STATEMENTS | 1 | | GLOSSARY OF TERMS | 3 | | CORPORATE STRUCTURE | 6 | | GENERAL DEVELOPMENT OF THE BUSINESS | 7 | | DESCRIPTION OF THE BUSINESS | 11 | | RISK FACTORS | 36 | | DESCRIPTION OF SECURITIES | 55 | | D ...

Company Overview - BriaCell Therapeutics Corp is a clinical-stage immunotherapy company focused on developing treatments to boost the body's cancer-fighting cells to destroy cancerous tumors, including BriaIMT™ for advanced breast cancer[4] - The company has recruited 35 patients showing robust response and is developing next-generation HLA-type matching therapies from a saliva test[4] - BriaCell's CEO has been involved in eleven drug approvals[5, 13, 62] Clinical Pipeline and Strategy - BriaCell is developing Bria-IMT™ combined with immune checkpoint inhibitors and Incyte's selected compounds for advanced breast cancer[4] - BriaCell is also developing Bria-OTS™ "Off-The-Shelf Personalized" immunotherapy based on patient's HLA-type[4] - The company believes tumor regression is most pronounced in patients who match Bria-IMT™ at specific HLA-types and develop an immune response[36] - BriaCell is engineering 15 unique HLA types (molecules), collectively referred to as Bria-OTS™, allowing for treatment of over 99% of patients[53] Clinical Trial Data - In a Phase I/IIa study, 23 patients were dosed with Bria-IMT™ monotherapy, showing similar or superior data to other advanced breast cancer drugs at a similar stage[34] - In HLA-matched patients (N=6, ≥ 2 matches), tumor shrinkage was observed in 50% of patients, and 75% in immune responders[35] - In a combination therapy study with checkpoint inhibitors, all 3 patients with Grade I/II tumors had clinical benefit (100%)[48] Financials and Ownership - As of January 3, 2020, the recent share price was C$12.00, with basic shares outstanding of 722,000 and fully diluted shares outstanding of 936,500[57] - Basic market capitalization was C$8.7 million, with insider ownership at 33.5%[57] - Jamieson Bondarenko holds 119,856 shares (16.6%), Dr William Williams holds 67,064 shares (9.3%), and Dr Charles Wiseman holds 44,604 shares (6.2%)[58]